ArticleBlood cancer journal2025
Prospective systematic classification of causes of death in the course of multiple myeloma.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Jia Xiang JinHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-6574-7816
Britta BesemerDepartment of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.
Büsranur YilmazHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, Germany.
Mathias HänelDepartment of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.
Roland FenkDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
Uta BertschHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, Germany.
Kaarina-Jiayuan GuHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, Germany.
Christine HanounDepartment for Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
Igor W BlauMedical Clinic, Charité University Medicine Berlin, Berlin, Germany.
Christoph MannDepartment for Hematology, Oncology and Immunology, University Hospital Gießen and Marburg, Marburg, Germany.
Christof ScheidDepartment of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
Roland SchroersHematology and Oncology, Knappschaft Kliniken, University Hospital Bochum, Bochum, Germany.
Ivana von MetzlerGoethe-University Frankfurt, University Hospital, Department of Medicine II - Hematology and Oncology, Frankfurt am Main, Germany.
Manfred HenselMannheimer Onkologie Praxis, Mannheim, Germany.
Eva-Maria KleinDepartment of Internal Medicine 5, Klinikum Nuremberg, Paracelsus Medical University, Nuremberg, Germany.
Martin HoffmannMedical Clinic A, Clinic Ludwigshafen, Ludwigshafen, Germany.
Christoph LutzHematology / Oncology Center, Koblenz, Germany.
Hendrik RiesenbergHematology / Oncology Center, Bielefeld, Germany.
Uwe M MartensHematology, Oncology, Palliative Care, SLK-Clinics Heilbronn, Heilbronn, Germany.ORCID http://orcid.org/0000-0001-7999-4359
Christian S MichelDepartment of Internal Medicine III, University Hospital Mainz, Mainz, Germany.ORCID http://orcid.org/0009-0004-1596-3763
Christian KunzHematology and Oncology, Westpfalz-Klinikum, Kaiserslautern, Germany.
Evgenii ShumilovMedical Clinic A, University Hospital Münster, Münster, Germany.
Deniz GezerDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Tobias A W HolderriedDepartment of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-2474-523X
Karolin Trautmann-GrillDepartment of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0002-9050-1049
Carsten Müller-TidowHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7166-5232
Katja C WeiselDepartment of Oncology, Hematology and BMT with Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0001-9422-6614
Marc S RaabHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4181-6922
Hans J SalwenderAsklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.ORCID http://orcid.org/0000-0001-7803-0814
Hartmut GoldschmidtHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-0961-0035
Elias K MaiHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, Germany. elias.mai@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-6226-1252
Funding
Dietmar Hopp Stiftung 1DH1811373
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.